280 related articles for article (PubMed ID: 16543688)
1. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Shoda J; Kanno Y; Suzuki H
Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
[TBL] [Abstract][Full Text] [Related]
2. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
3. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H
Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
[TBL] [Abstract][Full Text] [Related]
6. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
[TBL] [Abstract][Full Text] [Related]
7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
9. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
10. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
[TBL] [Abstract][Full Text] [Related]
11. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Matsuda H; Hayashi K; Homma K; Yoshioka K; Kanda T; Takamatsu I; Tatematsu S; Wakino S; Saruta T
Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
[TBL] [Abstract][Full Text] [Related]
12. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
15. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin blockade in late autosomal dominant polycystic kidney disease.
Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Moore CG; Perrone RD;
N Engl J Med; 2014 Dec; 371(24):2267-76. PubMed ID: 25399731
[TBL] [Abstract][Full Text] [Related]
17. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Abe H; Minatoguchi S; Ohashi H; Murata I; Minagawa T; Okuma T; Yokoyama H; Takatsu H; Takaya T; Nagano T; Osumi Y; Kakami M; Tsukamoto T; Tanaka T; Hiei K; Fujiwara H
Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
20. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]